Gilead Sciences Inc. (GILD) announced on Tuesday that it will buy a 49.
Gilead Sciences Inc. (GILD) said it expects to produce more than 2 million treatment courses of its experimental coronavirus drug candidate remdesivir by …
Gilead Sciences Inc.’s (GILD) remdesivir, its coronavirus drug candidate, is most “beneficial” for Covid-19 patients who require supplemental oxygen but don’t need mechanical …
Gilead Sciences Inc.’s (GILD) signed non-exclusive licensing agreements with five generic pharmaceutical manufacturers that will allow them to produce and sell its experimental …
Gilead Sciences (GILD) shares popped over 16% in after-hours trading on Thursday following encouraging anecdotal data from Gilead’s remdesivir COVID-19 trials. News source …
The majority of a small group of coronavirus patients showed their condition improve after treatment with remdesivir, an experimental drug being developed by …
Gilead Sciences Inc. (GILD) and Second Genome have entered into a four-year partnership aimed at joining forces in biomarker research and discovery of …
Gilead Sciences Inc. (GILD) said it is expecting to have initial remdesivir drug data in coming weeks.
Sangamo Therapeutics Inc (NASDAQ:SGMO) has just announced a strategic collaboration with Gilead Sciences, Inc’s (NASDAQ:GILD) company Kite, and shares are putting together a massive …
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the China Food and Drug Administration (CFDA) has approved Sovaldi® (sofosbuvir 400mg), a once-daily oral nucleotide analog polymerase …